185 related articles for article (PubMed ID: 37891423)
21. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.
Jegadeesh N; Liu Y; Zhang C; Zhong J; Cassidy RJ; Gillespie T; Kucuk O; Rossi P; Master VA; Alemozaffar M; Jani AB
Cancer; 2017 Feb; 123(3):512-520. PubMed ID: 27859018
[TBL] [Abstract][Full Text] [Related]
22. Mid-term oncologic outcomes of radical prostatectomy in lymph node metastatic prostate cancer patients.
Berchiche W; Long Depaquit T; Baboudjian M; Barret É; Rozet F; Cathelineau X; Bastide C
Prog Urol; 2023 Aug; 33(8-9):437-445. PubMed ID: 37248105
[TBL] [Abstract][Full Text] [Related]
23. Explainable machine learning predicts survival of retroperitoneal liposarcoma: A study based on the SEER database and external validation in China.
Wang M; Li Z; Zeng S; Wang Z; Ying Y; He W; Zhang Z; Wang H; Xu C
Cancer Med; 2024 Jun; 13(11):e7324. PubMed ID: 38847519
[TBL] [Abstract][Full Text] [Related]
24. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes.
Mazzone E; Preisser F; Nazzani S; Tian Z; Bandini M; Gandaglia G; Fossati N; Montorsi F; Graefen M; Shariat SF; Saad F; Briganti A; Karakiewicz PI
Eur Urol Oncol; 2019 Sep; 2(5):541-548. PubMed ID: 31411992
[TBL] [Abstract][Full Text] [Related]
25. Multiparametric MRI-based radiomics model to predict pelvic lymph node invasion for patients with prostate cancer.
Zheng H; Miao Q; Liu Y; Mirak SA; Hosseiny M; Scalzo F; Raman SS; Sung K
Eur Radiol; 2022 Aug; 32(8):5688-5699. PubMed ID: 35238971
[TBL] [Abstract][Full Text] [Related]
26. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score.
Schiavina R; Borghesi M; Brunocilla E; Manferrari F; Fiorentino M; Vagnoni V; Baccos A; Pultrone CV; Rocca GC; Rizzi S; Martorana G
BJU Int; 2013 Jun; 111(8):1237-44. PubMed ID: 23331345
[TBL] [Abstract][Full Text] [Related]
27. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer.
Briganti A; Chun FK; Salonia A; Gallina A; Farina E; Da Pozzo LF; Rigatti P; Montorsi F; Karakiewicz PI
BJU Int; 2006 Oct; 98(4):788-93. PubMed ID: 16796698
[TBL] [Abstract][Full Text] [Related]
28. Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement.
Godoy G; Chong KT; Cronin A; Vickers A; Laudone V; Touijer K; Guillonneau B; Eastham JA; Scardino PT; Coleman JA
Eur Urol; 2011 Aug; 60(2):195-201. PubMed ID: 21257258
[TBL] [Abstract][Full Text] [Related]
29. External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection.
Hansen J; Rink M; Bianchi M; Kluth LA; Tian Z; Ahyai SA; Shariat SF; Briganti A; Steuber T; Fisch M; Graefen M; Karakiewicz PI; Chun FK
Prostate; 2013 Jan; 73(2):211-8. PubMed ID: 22821742
[TBL] [Abstract][Full Text] [Related]
30. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
[TBL] [Abstract][Full Text] [Related]
31. Body Mass Index and prostatic-specific antigen are predictors of prostate cancer metastases in patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection.
Porcaro AB; Tafuri A; Sebben M; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Cacciamani GE; Brunelli M; Siracusano S; Cerruto MA; Artibani W
Minerva Urol Nefrol; 2019 Oct; 71(5):516-523. PubMed ID: 31241272
[TBL] [Abstract][Full Text] [Related]
32. Predicting survival of patients with node-positive prostate cancer following multimodal treatment.
Abdollah F; Karnes RJ; Suardi N; Cozzarini C; Gandaglia G; Fossati N; Bianchi M; Boorjian SA; Sun M; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol; 2014 Mar; 65(3):554-62. PubMed ID: 24094576
[TBL] [Abstract][Full Text] [Related]
33. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
34. Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer.
Sabbagh A; Washington SL; Tilki D; Hong JC; Feng J; Valdes G; Chen MH; Wu J; Huland H; Graefen M; Wiegel T; Böhmer D; Cowan JE; Cooperberg M; Feng FY; Roach M; Trock BJ; Partin AW; D'Amico AV; Carroll PR; Mohamad O
Eur Urol Oncol; 2023 Oct; 6(5):501-507. PubMed ID: 36868922
[TBL] [Abstract][Full Text] [Related]
35. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.
Bravi CA; Droghetti M; Fossati N; Gandaglia G; Suardi N; Mazzone E; Cucchiara V; Scuderi S; Barletta F; Schiavina R; Osmonov D; Juenemann KP; Boeri L; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768
[TBL] [Abstract][Full Text] [Related]
36. Risk of lymph node metastases in pathological gleason score≤6 prostate adenocarcinoma: Analysis of institutional and population-based databases.
Wenger H; Weiner AB; Razmaria A; Paner GP; Eggener SE
Urol Oncol; 2017 Jan; 35(1):31.e1-31.e6. PubMed ID: 27692833
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen associates with extensive lymph node invasion in high-risk prostate cancer.
Porcaro AB; Corsi P; Inverardi D; Sebben M; Tafuri A; Processali T; Mattevi D; De Marchi D; Pirozzi M; Cerruto MA; Amigoni N; Rizzetto R; Brunelli M; Siracusano S; Artibani W
Tumori; 2018 Aug; 104(4):307-311. PubMed ID: 29714659
[TBL] [Abstract][Full Text] [Related]
38. Deep learning models for predicting the survival of patients with chondrosarcoma based on a surveillance, epidemiology, and end results analysis.
Yan L; Gao N; Ai F; Zhao Y; Kang Y; Chen J; Weng Y
Front Oncol; 2022; 12():967758. PubMed ID: 36072795
[TBL] [Abstract][Full Text] [Related]
39. Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.
Briganti A; Karakiewicz PI; Chun FK; Suardi N; Gallina A; Abdollah F; Freschi M; Doglioni C; Rigatti P; Montorsi F
Int J Urol; 2009 Aug; 16(8):676-81. PubMed ID: 19602006
[TBL] [Abstract][Full Text] [Related]
40. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
